Name: Lariatin A
Brand: Biolinks K.K.
SKU: BLK-1010

For Research Use Only. Not for human or veterinary use.

Lariatin A Product ID: BLK-1010 Mechanism Lasso peptide antibiotic Primary Target Not fully defined (intracellular mycobacterial target) Pathway Antimicrobial peptide pathway
Structure
Molecular Formula	C94H143N27O25
Molecular Weight	2051.35
Price	1mg: USD 300.00 / 5mg: - / 25mg: -
Storage	-20°C
Solubility	1mg/ml methanol, water
Purity	>95% [View LC/UV Data]
Source Organism	Rhodococcus jostii.
Summary	Lariatin A is a lasso-structured peptide antibiotic active against Mycobacterium species.
Details	Lariatin A is a ribosomally synthesized and post-translationally modified peptide (RiPP) produced by Rhodococcus jostii K01-B0171. It consists of 18 L-amino acids forming a unique lasso structure in which the C-terminal tail (Trp9-Pro18) threads through an N-terminal macrolactam ring formed between Gly1 and the γ-carboxyl group of Glu8. NMR and molecular dynamics studies confirmed this threaded topology. Lariatin A exhibits potent antimycobacterial activity, including inhibition of Mycobacterium smegmatis and Mycobacterium tuberculosis (MIC ~0.39 µg/mL). Functional studies demonstrated that Lys17 is essential for antimicrobial activity, likely via salt-bridge interactions stabilizing the lasso conformation. Although the precise intracellular molecular target remains unidentified, lariatin A represents a structurally distinct antimycobacterial peptide scaffold with therapeutic potential.
Browse Related	Mechanism Lasso peptide antibiotic Open full index Primary Target Not fully defined (intracellular mycobacterial target) Open full index Pathway Antimicrobial peptide pathway Open full index Chemical Class Lasso peptide (RiPP) Open full index
Mechanism	Lasso peptide antibiotic
Primary Target	Not fully defined (intracellular mycobacterial target)
Pathway	Antimicrobial peptide pathway
Chemical Class	Lasso peptide (RiPP)
Discovery Year	2007
Keywords	lasso peptide ribosomally synthesized and post-translationally modified peptide antimycobacterial compound mycobacterium tuberculosis inhibitor rhodococcus metabolite ripp research scaffold
References	Iwatsuki et al., J Am Chem Soc, 2006 DOI: 10.1021/ja056780z Iwatsuki et al., J Antibiot, 2007 DOI: 10.1038/ja.2007.48 Inokoshi et al., Bioorg Med Chem Lett, 2009 DOI: 10.1016/j.bmcl.2009.03.033
Request pricing, availability, or bulk supply information for this compound. Get a Quote General Inquiry
Documents 📄 Safety Data Sheet (SDS) – Download PDF 📄 Product Specification Sheet (PDS) – Download PDF 🧪 Certificate of Manufacture (CofM) – Download HTML
← Back to Catalog
Representative LC/UV Data HPLC Conditions (typical): Column: C18 Mobile phase: 5–100% ACN / H2O (0.05% H3PO4), linear gradient 20 min Flow rate: 0.2 mL/min Detection: 210 nm Representative analytical data. Actual batch data may vary.